Literature DB >> 35371099

Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure.

Pavanish Kumar1,2, Amanda Lim1, Su Li Poh1, Sharifah Nur Hazirah1, Camillus Jian Hui Chua1, Nursyuhadah Binte Sutamam1, Thaschawee Arkachaisri3,4, Joo Guan Yeo1,3,4, Theo Kofidis5,6, Vitaly Sorokin5, Carolyn S P Lam7,8, Arthur Mark Richards6, Salvatore Albani1,3,4.   

Abstract

Chronic heart failure (HF) is a syndrome of heterogeneous etiology associated with multiple co-morbidities. Inflammation is increasingly recognized as a key contributor to the pathophysiology of HF. Heterogeneity and lack of data on the immune mechanism(s) contributing to HF may partially underlie the failure of clinical trials targeting inflammatory mediators. We studied the Immunome in HF cohort using mass cytometry and used data-driven systems immunology approach to discover and characterize modulated immune cell subsets from peripheral blood. We showed cytotoxic and inflammatory innate lymphoid and myeloid cells were expanded in HF patients compared to healthy controls. Network analysis showed highly modular and centralized immune cell architecture in healthy control immune cell network. In contrast, the HF immune cell network showed greater inter-cellular communication and less modular structure. Furthermore, we found, as an immune mechanism specific to HF with preserved ejection fraction (HFpEF), an increase in inflammatory MAIT and CD4 T cell subsets.
Copyright © 2022 Kumar, Lim, Poh, Hazirah, Chua, Sutamam, Arkachaisri, Yeo, Kofidis, Sorokin, Lam, Richards and Albani.

Entities:  

Keywords:  CyTOF; cardiovascular disease; heart failure; immunity; inflammation; network biology; systems immunology

Mesh:

Year:  2022        PMID: 35371099      PMCID: PMC8964981          DOI: 10.3389/fimmu.2022.817514

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  44 in total

1.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

2.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.

Authors:  B Bozkurt; S B Kribbs; F J Clubb; L H Michael; V V Didenko; P J Hornsby; Y Seta; H Oral; F G Spinale; D L Mann
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

3.  Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.

Authors:  Barry A Borlaug; Margaret M Redfield
Journal:  Circulation       Date:  2011-05-10       Impact factor: 29.690

4.  Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.

Authors:  N Sivasubramanian; M L Coker; K M Kurrelmeyer; W R MacLellan; F J DeMayo; F G Spinale; D L Mann
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

5.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.

Authors:  J Parrish-Novak; S R Dillon; A Nelson; A Hammond; C Sprecher; J A Gross; J Johnston; K Madden; W Xu; J West; S Schrader; S Burkhead; M Heipel; C Brandt; J L Kuijper; J Kramer; D Conklin; S R Presnell; J Berry; F Shiota; S Bort; K Hambly; S Mudri; C Clegg; M Moore; F J Grant; C Lofton-Day; T Gilbert; F Rayond; A Ching; L Yao; D Smith; P Webster; T Whitmore; M Maurer; K Kaushansky; R D Holly; D Foster
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

Review 6.  Heart failure drug treatment.

Authors:  Patrick Rossignol; Adrian F Hernandez; Scott D Solomon; Faiez Zannad
Journal:  Lancet       Date:  2019-03-09       Impact factor: 79.321

7.  Pro-inflammatory, IL-17 pathways dominate the architecture of the immunome in pediatric refractory epilepsy.

Authors:  Pavanish Kumar; Derrick Chan Wei Shih; Amanda Lim; Bhairav Paleja; Simon Ling; Lai Li Yun; Su Li Poh; Adeline Ngoh; Thaschawee Arkachaisri; Joo Guan Yeo; Salvatore Albani
Journal:  JCI Insight       Date:  2019-03-26

8.  Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure.

Authors:  Donna L Vredevoe; Mel Widawski; Gregg C Fonarow; Michele Hamilton; Otoniel Martínez-Maza; Julia R Gage
Journal:  Am J Cardiol       Date:  2004-04-15       Impact factor: 2.778

9.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

Review 10.  Evaluation and management of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.